Zu lab Publications
Leukocyte immunoglobulin-like receptor B1 (LILRB1) protects human multiple myeloma cells from ferroptosis by maintaining cholesterol homeostasis
Xian, M, Wang, Q, Xiao, L, Zhong, L, Xiong, W, Ye, L, Su, P, Zhang, C, Li, Y, Orlowski, RZ, Zhan, F, Ganguly, S, Zu, Y, Qian, J & Yi, Q 2024, , Nature Communications, vol. 15, no. 1, 5767. https://doi.org/10.1038/s41467-024-50073-x
Development of therapeutic monoclonal antibodies against DKK1 peptide-HLA-A2 complex to treat human cancers
Qian, J, Wang, Q, Xiao, L, Xiong, W, Xian, M, Su, P, Yang, M, Zhang, C, Li, Y, Zhong, L, Ganguly, S, Zu, Y & Yi, Q 2024, , Journal for immunotherapy of cancer, vol. 12, no. 1, e008145. https://doi.org/10.1136/jitc-2023-008145
DNA mismatch repair defect and intratumor heterogeneous deficiency differently impact immune responses in diffuse large B-cell lymphoma
Xu-Monette, ZY, Luo, C, Yu, L, Li, Y, Bhagat, G, Tzankov, A, Visco, C, Fan, X, Dybkaer, K, Sakhdari, A, Wang, NT, Yuan, AF, Chiu, A, Tam, W, Zu, Y, Hsi, ED, Perry, AM, Song, W, O’Malley, D, Au, Q, Nunns, H, Go, H, Møller, MB, Parsons, BM, Montes-Moreno, S, Ponzoni, M, Ferreri, AJM, Sohani, AR, Abramson, JS, Xu, B & Young, KH 2024, , OncoImmunology, vol. 13, no. 1, 2384667. https://doi.org/10.1080/2162402X.2024.2384667
LILRB3 Modulates Acute Myeloid Leukemia Progression and Acts as an Effective Target for CAR T-cell Therapy
Mai, S, Hodges, A, Chen, HM, Zhang, J, Wang, YL, Liu, Y, Nakatsu, F, Wang, X, Fang, J, Xu, Y, Davidov, V, Kang, K, Pingali, SR, Ganguly, S, Suzuki, M, Konopleva, M, Prinzing, B, Zu, Y, Gottschalk, S, Lu, Y, Chen, SH & Pan, PY 2023, , Cancer research, vol. 83, no. 24, pp. 4047-4062. https://doi.org/10.1158/0008-5472.CAN-22-2483
Cell-free DNA 5-hydroxymethylcytosine is highly sensitive for MRD assessment in acute myeloid leukemia
Shao, J, Shah, S, Ganguly, S, Zu, Y, He, C & Li, Z 2023, , Clinical Epigenetics, vol. 15, no. 1, 134. https://doi.org/10.1186/s13148-023-01547-0
Classification of Acute Myeloid Leukemia by Cell-Free DNA 5-Hydroxymethylcytosine
Shao, J, Shah, S, Ganguly, S, Zu, Y, He, C & Li, Z 2023, , Genes, vol. 14, no. 6, 1180. https://doi.org/10.3390/genes14061180
EBV-positive DLBCL frequently harbors somatic mutations associated with clonal hematopoiesis of indeterminate potential
Li, Y, Xu-Monette, ZY, Abramson, J, Sohani, AR, Bhagat, G, Tzankov, A, Visco, C, Zhang, S, Dybkaer, K, Pan, Z, Xu, M, Tam, W, Zu, Y, Hsi, ED, Hagemeister, FB, Go, H, van Krieken, JH, Winter, JN, Ponzoni, M, Ferreri, AJM, Møller, MB, Piris, MA, Wang, Y, Zhang, M & Young, KH 2023, , Blood Advances, vol. 7, no. 7, pp. 1308-1311. https://doi.org/10.1182/bloodadvances.2022008550
Tumor-Infiltrating Normal B Cells Revealed by Immunoglobulin Repertoire Clonotype Analysis Are Highly Prognostic and Crucial for Antitumor Immune Responses in DLBCL
Xu-Monette, ZY, Li, Y, Snyder, T, Yu, T, Lu, T, Tzankov, A, Visco, C, Bhagat, G, Qian, W, Dybkaer, K, Chiu, A, Tam, W, Zu, Y, Hsi, ED, Hagemeister, FB, Wang, Y, Go, H, Ponzoni, M, Ferreri, AJM, Møller, MB, Parsons, BM, Fan, X, van Krieken, JH, Piris, MA, Winter, JN, Au, Q, Kirsch, I, Zhang, M, Shaughnessy, J, Xu, B & Young, KH 2023, , Clinical Cancer Research, vol. 29, no. 23, pp. 4808-4821. https://doi.org/10.1158/1078-0432.CCR-23-1554
Cell-free DNA 5-hydroxymethylcytosine is an emerging marker of acute myeloid leukemia
Shao, J, Wang, S, West-Szymanski, D, Karpus, J, Shah, S, Ganguly, S, Smith, J, Zu, Y, He, C & Li, Z 2022, , Scientific Reports, vol. 12, no. 1, 12410, pp. 12410. https://doi.org/10.1038/s41598-022-16685-3
MYCN-driven fatty acid uptake is a metabolic vulnerability in neuroblastoma
Tao, L, Mohammad, MA, Milazzo, G, Moreno-Smith, M, Patel, TD, Zorman, B, Badachhape, A, Hernandez, BE, Wolf, AB, Zeng, Z, Foster, JH, Aloisi, S, Sumazin, P, Zu, Y, Hicks, J, Ghaghada, KB, Putluri, N, Perini, G, Coarfa, C & Barbieri, E 2022, , Nature Communications, vol. 13, no. 1, 3728, pp. 3728. https://doi.org/10.1038/s41467-022-31331-2
A novel role of lysophosphatidic acid (LPA) in human myeloma resistance to proteasome inhibitors
Su, P, Xiao, L, Ye, L, Wang, Z, Xiong, W, Wang, Q, Ma, X, Xian, M, Yang, M, Zu, Y, Pingali, SR, Qian, J & Yi, Q 2022, , Journal of Hematology and Oncology, vol. 15, no. 1, 55, pp. 55. https://doi.org/10.1186/s13045-022-01269-5
Aptamer–Gemcitabine Conjugates with Enzymatically Cleavable Linker for Targeted Delivery and Intracellular Drug Release in Cancer Cells
Qi, J, Zeng, Z, Chen, Z, Nipper, C, Liu, X, Wan, Q, Chen, J, Tung, CH & Zu, Y 2022, , Pharmaceuticals, vol. 15, no. 5, 558. https://doi.org/10.3390/ph15050558
Aptamer Targets Triple-Negative Breast Cancer through Specific Binding to Surface CD49c
Wan, Q, Zeng, Z, Qi, J, Zhao, Y, Liu, X, Chen, Z, Zhou, H & Zu, Y 2022, , Cancers, vol. 14, no. 6, 1570. https://doi.org/10.3390/cancers14061570
Genetic Subtyping and Phenotypic Characterization of the Immune Microenvironment and MYC/BCL2 Double Expression Reveal Heterogeneity in Diffuse Large B-cell Lymphoma
Xu-Monette, ZY, Wei, L, Fang, X, Au, Q, Nunns, H, Nagy, M, Tzankov, A, Zhu, F, Visco, C, Bhagat, G, Dybkaer, K, Chiu, A, Tam, W, Zu, Y, Hsi, ED, Hagemeister, FB, Sun, X, Han, X, Go, H, Ponzoni, M, Ferreri, AJM, Møller, MB, Parsons, BM, van Krieken, JH, Piris, MA, Winter, JN, Li, Y, Xu, B, Albitar, M, You, H & Young, KH 2022, , Clinical Cancer Research, vol. 28, no. 5, pp. 972-983. https://doi.org/10.1158/1078-0432.CCR-21-2949
Determining clinical course of diffuse large B-cell lymphoma using targeted transcriptome and machine learning algorithms
Albitar, M, Zhang, H, Goy, A, Xu-Monette, ZY, Bhagat, G, Visco, C, Tzankov, A, Fang, X, Zhu, F, Dybkaer, K, Chiu, A, Tam, W, Zu, Y, Hsi, ED, Hagemeister, FB, Huh, J, Ponzoni, M, Ferreri, AJM, Møller, MB, Parsons, BM, van Krieken, JH, Piris, MA, Winter, JN, Li, Y, Xu, B & Young, KH 2022, , Blood Cancer Journal, vol. 12, no. 2, 25, pp. 25. https://doi.org/10.1038/s41408-022-00617-5
Next-Generation Sequencing Revealed a Distinct Immunoglobulin Repertoire with Specific Mutation Hotspots in Acute Myeloid Leukemia
Xia, M, Wu, L, Sun, X, Han, X, Yan, H, Huang, J, Zhang, Y, Hu, Z, Zu, Y, Yin, CC & Qiu, X 2022, , Biology, vol. 11, no. 2, 161. https://doi.org/10.3390/biology11020161
RAR? activation sensitizes human myeloma cells to carfilzomib treatment through the OAS-RNase L innate immune pathway
Wang, Q, Lin, Z, Wang, Z, Ye, L, Xian, M, Xiao, L, Su, P, Bi, E, Huang, YH, Qian, J, Liu, L, Ma, X, Yang, M, Xiong, W, Zu, Y, Pingali, SR, Xu, B & Yi, Q 2022, , Blood, vol. 139, no. 1, pp. 59-72. https://doi.org/10.1182/blood.2020009856
Aptamer-armed nanostructures improve the chemotherapy outcome of triple-negative breast cancer
Wan, Q, Zeng, Z, Qi, J, Chen, Z, Liu, X & Zu, Y 2022, , Molecular Therapy, vol. 30, no. 6, pp. 2242-2256. https://doi.org/10.1016/j.ymthe.2022.02.004
Poor Humoral Response in Solid Organ Transplant Recipients Following Complete mRNA SARS-CoV-2 Vaccination
Cao, J, Liu, X, Muthukumar, A, Gagan, J, Jones, P & Zu, Y 2022, , Clinical Chemistry, vol. 68, no. 1, pp. 251-253. https://doi.org/10.1093/clinchem/hvab149
RAR? activation sensitizes human myeloma cells to carfilzomib treatment through the OAS-RNase L innate immune pathway
Wang, Q, Lin, Z, Wang, Z, Ye, L, Xian, M, Xiao, L, Su, P, Bi, E, Huang, YH, Qian, J, Liu, L, Ma, X, Yang, M, Xiong, W, Zu, Y, Pingali, SR, Xu, B & Yi, Q 2022, , Blood, vol. 139, no. 1, pp. 59-72. https://doi.org/10.1182/blood.2020009856, https://doi.org/10.1182/blood.2020009856